{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-274093","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2026-06-17T20:00:15+00:00","discovered_at":"2026-06-17T20:01:00.368994+00:00","generated_at":"2026-06-17T20:01:20.502511+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Damora Therapeutics shareholders elect directors, approve say-on-pay and E&Y ratification at 2026 annual meeting","bullets":["Elected Michael Landsittel and Cameron Turtle as Class III directors; ~51.4M votes for each, 29K withheld.","Advisory say-on-pay approved: 51,401,988 for, 3,546 against, 27,018 abstain.","Say-on-frequency: one-year option received 50,913,167 votes; Board adopts annual frequency.","Ratified Ernst & Young as auditor for FY2026: 54,977,317 for, 5,640 against, 26,981 abstain.","Quorum of 55,009,938 shares out of 60,303,212 outstanding was represented."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-274093","json":"https://secwatch.observer/filing/0001193125-26-274093.json","markdown":"https://secwatch.observer/filing/0001193125-26-274093.md","text":"https://secwatch.observer/filing/0001193125-26-274093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/dmra-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:01:20.502511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"533e67cbff731a953da1df48742663e329b73736","claim":"Damora Therapeutics, Inc. shareholders approved Election of Michael Landsittel and Cameron Turtle, D.Phil as Class III directors at the 2026-06-17 meeting.","evidence_excerpt":"1. Election of Directors Proposal . Nominees For Withheld Broker Non-Votes Michael Landsittel 51,403,541 29,011 3,577,386 Cameron Turtle, D.Phil 51,403,540 29,012 3,577,386","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"587b91870e68afd6f552dfa38d64eb2903e2036e","claim":"Damora Therapeutics, Inc. shareholders approved Advisory vote to approve the compensation paid to the named executive officers at the 2026-06-17 meeting.","evidence_excerpt":"2. Say-on-Pay Proposal . For Against Abstain Broker Non-Votes 51,401,988 3,546 27,018 3,577,386","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"be40b60508a69f4b4d334753ecbada368aecab1e","claim":"Damora Therapeutics, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve executive compensation at the 2026-06-17 meeting.","evidence_excerpt":"3. Say-on-Frequency Proposal . 1 Year 2 Years 3 Years Abstain 50,913,167 103 518,015 1,267","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"d276d1f741f2760a54104d6357c07b0c91976061","claim":"Damora Therapeutics, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.","evidence_excerpt":"4. Ratification of Auditor Proposal . For Against Abstain Broker Non-Votes 54,977,317 5,640 26,981 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/0001193125-26-274093-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}